ACG-ANTITUMOUR · Design, synthesis and biological studies of novel 1,4-benzoxazepines as antitumour compounds
6РП — Действия „Мария Кюри“
- Период
- 2006-04-01 → 2007-03-31
- Финансиране от ЕС
- 40 000 €
- Участници
- 1
- Схема
- ERG
Линиите свързват координатора с партньорите.
Накратко на български
Нови химични съединения от групата на 1,4-бензоксазепините се тестват за действие срещу рак на гърдата. Това помага да се разбере как тези молекули спират размножаването на туморните клетки и чрез кои механизми действат на молекулярно ниво.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Цел на проекта
Breast cancer remains the most common cancer in women and is the most frequent cause of cancer death. Over the past 20 years, the 5-year survival for patients with breast cancer has increased by around 10%, largely as a result of earlier diagnosis and better treatment. Nevertheless, 5-year survival rates for people with breast cancer range between 60% and 70%, and many patients still die from the disease. Although 5-fluorouracil (5-FU) was first introduced in 1957, it remains an essential part of the treatment of a wide range of solid tumours. Although this antimetabolite is toxic, its efficacy makes it one of the most widely used agents against solid tumours. 5-FU-containing acyclonucleosides have been reported to induce myogenic differentiation in rhabdomy osarcoma cells, suggesting that these drugs might be useful for differentiation therapy in this type of tumour. Such a therapy is an attractive approach to cancer treatment, which assumes that neoplastic transformation reveals the inability of a cell popul ation to couple proliferation and differentiation signals. Following these results a series of 1,4-benzoxazepines linked to natural or synthesised bases is proposed. A library of compounds will be synthesized in solid phase to rapidly obtain the maximum structural variety. The compounds will be tested as in vitro antiproliferative, apoptotic and cell cycle drug-acting agents against breast cancer. Biological studies will be carried out to determine the mechanism of action at the molecular level. QSAR, SAR and molecular modelling studies will be developed throughout the project. The information obtained from these structure-activity relationships will be valuable to determine which parts of the synthesized molecules are essentially involved in the activity and potency. The anticancer activity of the most potent and less toxic compounds will be assayed in mice.
Оригинален текст от CORDIS (на английски).
Участници
- UNIVERSIDAD DE GRANADA · GRANADAКоординаторИспания
Връзки
Данни: CORDIS, © Европейски съюз